We will obtain cDNAs of the up-regulated proteins previously published: CD30 ligand, endostatin, HSP90alpha, MIP-4, pleiotrophin, PFKCI, and YES (a tyrosine kinase oncogene).
Based on our previous studies, a panel consisting of thirteen protein biomarkers will be used for determining presence or absence of autoantibodies in serum specimen. The 13-protein marker panel consisting of purified full-length recombinant proteins are c-myc, cyclin A, cyclin B1, cyclin D1, CDK2, survivin, CD30 ligand, endostatin, HSP90alpha, MIP-4, pleiotrophin, PRKCI, and YES.
Lung and Upper Aerodigestive Cancers Research Group
We hypothesize that our novel Biomarker Panel of Auto-antibodies can distinguish aggressive, symptom diagnosed lung cancer from non-aggressive, screen-detected lung cancer.
Specific Aim 1. Develop a novel biomarker panel based on our auto-antibody publication and our development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology. Specific Aim 2. Test the autoantibody panels on CT-scan screen-detected lung cancers including both indolent and aggressive cancers, and validate with thoracic surgery lung cancer cases stratified by no recurrence within three years “indolent” and recurrent within three years “aggressive.” Each lung cancer case will be matched to a control with normal CT scans by smoking, gender, and age.
development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology.
Each sample will be assessed in triplicates, and the average value at 490 nm will be used for data analysis. During the 02 year we will be focusing our efforts at completing the assays and data analysis.
Thank you to everyone who contributed to the successful and productive EDRN Orientation Meeting in October. The next EDRN Steering Committee Meeting will take place in March 6-9, 2017 in Tempe, AZ. More information about this meeting will be available soon.